Title : Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease - Sanchez Montero _2021_Eur.J.Pharmacol__173875 |
Author(s) : Sanchez Montero JM , Agis-Torres A , Solano D , Sollhuber M , Fernandez M , Villaro W , Gomez-Canas M , Garcia-Arencibia M , Fernandez-Ruiz J , Egea J , Martin MI , Giron R |
Ref : European Journal of Pharmacology , :173875 , 2021 |
Abstract :
Given that neuronal degeneration in Alzheimer's disease (AD) is caused by the combination of multiple neurotoxic insults, current directions in the research of novel therapies to treat this disease attempts to design multitarget strategies that could be more effective than the simply use of acetylcholinesterase inhibitors; currently, the most used therapy for AD. One option, explored recently, is the synthesis of new analogues of cannabinoids that could competitively inhibit the acetylcholinesterase (AChE) enzyme and showing the classic neuroprotective profile of cannabinoid compounds. In this work, molecular docking has been used to design some cannabinoid analogues with such multitarget properties, based on the similarities of donepezil and delta(9)-tetrahydrocannabinol. The analogues synthesized, compounds 1 and 2, demonstrated to have two interesting characteristics in different in vitro assays: competitive inhibition of AChE and competitive antagonism at the CB(1)/CB(2) receptors. They are highly lipophilic, highlighting that they could easily reach the CNS, and apparently presented a low toxicity. These results open the door to the synthesis of new compounds for a more effective treatment of AD. |
PubMedSearch : Sanchez Montero _2021_Eur.J.Pharmacol__173875 |
PubMedID: 33460612 |
Sanchez Montero JM, Agis-Torres A, Solano D, Sollhuber M, Fernandez M, Villaro W, Gomez-Canas M, Garcia-Arencibia M, Fernandez-Ruiz J, Egea J, Martin MI, Giron R (2021)
Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease
European Journal of Pharmacology
:173875
Sanchez Montero JM, Agis-Torres A, Solano D, Sollhuber M, Fernandez M, Villaro W, Gomez-Canas M, Garcia-Arencibia M, Fernandez-Ruiz J, Egea J, Martin MI, Giron R (2021)
European Journal of Pharmacology
:173875